{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Witzig TE"],"funding":["NCI NIH HHS"],"pagination":["328-35"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4504947"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["126(3)"],"pubmed_abstract":["Everolimus is an oral agent that targets the mammalian target of rapamycin (mTOR) pathway. This study investigated mTOR pathway activation in T-cell lymphoma (TCL) cell lines and assessed antitumor activity in patients with relapsed/refractory TCL in a phase 2 trial. The mTOR pathway was activated in all 6 TCL cell lines tested and everolimus strongly inhibited malignant T-cell proliferation with minimal cytotoxic effects. Everolimus completely inhibited phosphorylation of ribosomal S6, a raptor/mTOR complex 1 (mTORC1) target, without a compensatory activation of the rictor/mTORC2 target Akt (S475). In the clinical trial, 16 patients with relapsed TCL were enrolled and received everolimus 10 mg by mouth daily. Seven patients (44%) had cutaneous (all mycosis fungoides); 4 (25%) had peripher"],"journal":["Blood"],"pubmed_title":["The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma."],"pmcid":["PMC4504947"],"funding_grant_id":["P30 CA015083","CA127433","R01 CA127433","CA97274","P50 CA097274"],"pubmed_authors":["Habermann TM","Macon W","Johnston PB","Porrata LF","Nowakowski GS","Inwards DJ","Colgan JP","Witzig TE","Han JJ","Ansell SM","LaPlant B","Micallef IN","Tun HW","Reeder C","Gupta M","Stenson M","Markovic S"],"additional_accession":[]},"is_claimable":false,"name":"The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma.","description":"Everolimus is an oral agent that targets the mammalian target of rapamycin (mTOR) pathway. This study investigated mTOR pathway activation in T-cell lymphoma (TCL) cell lines and assessed antitumor activity in patients with relapsed/refractory TCL in a phase 2 trial. The mTOR pathway was activated in all 6 TCL cell lines tested and everolimus strongly inhibited malignant T-cell proliferation with minimal cytotoxic effects. Everolimus completely inhibited phosphorylation of ribosomal S6, a raptor/mTOR complex 1 (mTORC1) target, without a compensatory activation of the rictor/mTORC2 target Akt (S475). In the clinical trial, 16 patients with relapsed TCL were enrolled and received everolimus 10 mg by mouth daily. Seven patients (44%) had cutaneous (all mycosis fungoides); 4 (25%) had peripher","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Jul","modification":"2025-04-04T21:52:02.394Z","creation":"2019-03-27T01:55:14Z"},"accession":"S-EPMC4504947","cross_references":{"pubmed":["25921059"],"doi":["10.1182/blood-2015-02-629543"]}}